Emergence of institutional antithrombotic protocols for coronavirus 2019

INTRODUCTION The coronavirus disease 2019 (COVID‐19), first identified in December 2019 in Wuhan, China, is a major public health crisis with new infections increasing exponentially worldwide. 1 COVID‐19 is an acute infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SA...

Full description

Saved in:

Bibliographic Details
Published in:	Research and practice in thrombosis and haemostasis Vol. 4; no. 4; pp. 510 - 517
Main Authors:	Cohoon, Kevin P., Mahé, Guillaume, Tafur, Alfonso J., Spyropoulos, Alex C.
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01.05.2020 Elsevier Limited Wiley John Wiley and Sons Inc Elsevier
Subjects:	acute infectious disease anticoagulant Anticoagulants antiplatelet antithrombotic therapy Body mass index coronavirus Coronaviruses COVID-19 Cytokines deep vein thrombosis Disease prevention Enzymes Forum Heparan sulfate Hospitals Illnesses Infections Infectious diseases Influenza Laboratories Life Sciences Medical prognosis Mortality Pandemics Pneumonia pulmonary embolism Pulmonary embolisms pulmonary infection SARS‐CoV‐2 Severe acute respiratory syndrome coronavirus 2 Thromboembolism Thrombosis United States > US pulmonary infection deep vein thrombosis COVID‐19 SARS‐CoV‐2 acute infectious disease coronavirus anticoagulant antithrombotic therapy pulmonary embolism antiplatelet
ISSN:	2475-0379, 2475-0379
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!